Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Change in Account Payables (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Change in Account Payables for 7 consecutive years, with $426000.0 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Change in Account Payables fell 48.61% year-over-year to $426000.0, compared with a TTM value of $2.6 million through Dec 2019, up 508.8%, and an annual FY2024 reading of $1.1 million, up 383.13% over the prior year.
  • Change in Account Payables was $426000.0 for Q4 2019 at Larimar Therapeutics, down from $1.6 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $3.1 million in Q4 2015 and bottomed at -$4.1 million in Q1 2016.
  • Average Change in Account Payables over 5 years is $189950.0, with a median of $385000.0 recorded in 2017.
  • Peak annual rise in Change in Account Payables hit 766.47% in 2016, while the deepest fall reached 461.37% in 2016.
  • Year by year, Change in Account Payables stood at $3.1 million in 2015, then plummeted by 134.75% to -$1.1 million in 2016, then surged by 132.21% to $344000.0 in 2017, then soared by 140.99% to $829000.0 in 2018, then tumbled by 48.61% to $426000.0 in 2019.
  • Business Quant data shows Change in Account Payables for LRMR at $426000.0 in Q4 2019, $1.6 million in Q3 2019, and $1.1 million in Q2 2019.